Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program... Show more
Humana is one of the largest U.S. health insurers and a leading player in Medicare Advantage, the privately administered alternative to traditional Medicare that covers millions of seniors. Its scale in senior-focused coverage, combined with an integrated care-delivery arm — the CenterWell brand, which spans primary care, home health, and pharmacy — gives it a differentiated ability to manage medical costs through value-based care models.
The company's medium-term positioning hinges on rebuilding the quality of its plan portfolio. After a sharp ratings decline across 2025 and 2026, the recovery of its large contracts, including the roughly two-million-member H5216 plan back to four stars, restores eligibility for quality bonus payments and improves how plans appear to prospective members during the annual open-enrollment period. This strengthens Humana's competitive footing at a moment when some large rivals face their own ratings slippage.
Structurally, Humana is pruning less profitable markets — with plan exits expected to affect roughly 600,000 members in 2027 — and concentrating on higher-performing regions and special-needs plans. A new joint venture with BlackRock's HPS Investment Partners to manage nearly 150 CenterWell senior primary-care clinics is designed to reduce balance-sheet liabilities and add financial flexibility, supporting the broader effort to fund growth while restoring margins.
The most significant near-term events center on execution of the ratings-driven recovery. Humana's December 10, 2026 investor update is a key opportunity for management to quantify the expected 2028 quality-bonus impact, outline the 2027 benefit and bid strategy, and update its path toward the 2028 margin target. Clarity on how much bonus revenue is retained versus reinvested will heavily influence sentiment.
Quarterly earnings remain pivotal. The company has affirmed a 2026 adjusted EPS floor of at least $9.00 while revising GAAP (Generally Accepted Accounting Principles) EPS guidance lower, underscoring that near-term results still carry the drag of prior-year ratings. Investors will watch medical cost trends and membership retention during the 2027 open-enrollment season, which runs through early December.
Analyst rating trends have shifted from caution to a more balanced, increasingly constructive stance. The consensus profile now skews toward Buy or Moderate Buy, with an average price target around the mid-$400s. Recent moves include Baird's upgrade to Outperform with a $596 target, Barclays' $582 target tied to a 93% bonus mix, Oppenheimer's $525 target, and Raymond James' upgrade to Outperform with a $520 target. These revisions reflect rising conviction in a 2028 earnings inflection, though a meaningful minority of analysts retain Hold ratings, reflecting execution uncertainty and the binary nature of future ratings cycles.
Humana's trajectory is closely tied to government health policy and the economics of managed care. Medicare Advantage reimbursement rates, set annually by the Centers for Medicare and Medicaid Services (CMS), directly influence plan pricing, benefit richness, and margins. Proposals for flat or constrained rate updates, or expanded coverage mandates such as GLP-1 weight-loss drugs, could pressure profitability across the sector.
Medical cost trends are equally important. Elevated utilization, hospital pricing, and prescription-drug inflation can compress margins if they outpace government payment growth. Conversely, the moderating cost-trend environment some analysts cite is a tailwind for margin recovery. Interest rates and inflation also shape the financing of the CenterWell clinic network and capital-allocation decisions, while broader demographic aging underpins long-term demand for senior-focused care.
Regulatory scrutiny remains a live risk, including congressional inquiries into Affordable Care Act premium-subsidy practices and ongoing debate over risk-adjustment and coding rules. Political outcomes can influence reimbursement philosophy, making the policy cycle a structural swing factor for the entire managed-care group.
For investors tracking how these catalysts may shape near-term price action, Tickeron's Trend Prediction Engine offers an AI-powered forecasting tool designed to help identify whether a stock, ETF, or other asset may trend bullish, bearish, or sideways over the next week or month. It helps users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, with searchable categories, historical context, and alert-oriented functionality. As you monitor Humana's unfolding story, the Trend Prediction Engine can serve as a complementary signal alongside fundamental analysis.
Looking toward 2026 and beyond, Humana's investment narrative centers on a multiyear earnings recovery rather than near-term results. The 2027 Star Ratings improvement sets the stage for an estimated $4.8 billion in quality bonus payments in 2028, and several analysts model adjusted EPS reaching the mid-$30s by 2028 — a sharp rebound from the 2026 floor of at least $9.00. The credibility of that path depends on disciplined bidding, controlled medical costs, and member retention through the 2027 enrollment cycle.
Long-term themes include the strategic expansion of CenterWell's integrated care model, which positions Humana to capture value as care shifts toward primary-care-led, home-based delivery. Cost-structure evolution — including operating-cost reductions and the HPS clinic joint venture — is central to margin sustainability. Competitive threats from UnitedHealth, CVS Health's Aetna, and Elevance Health remain significant, as do regulatory developments around reimbursement and coding practices.
Capital-allocation priorities are another area to monitor: a disciplined buyback program and balance-sheet flexibility could support per-share value as earnings recover. While consensus expectations have become more optimistic, the wide spread between the lowest and highest price targets reflects genuine disagreement over how much of the ratings-driven upside converts into durable profitability — keeping execution, cost trends, and future ratings cycles at the center of the debate.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HUM has been closely correlated with UNH. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if HUM jumps, then UNH could also see price increases.
a company offers health insurance coverage and related services
Industry ManagedHealthCare
The Moving Average Convergence Divergence (MACD) for HUM turned positive on November 10, 2026. Looking at past instances where HUM's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on HUM as a result. In 53 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +5.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 223 of 349 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The 10-day RSI Indicator for HUM moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 18 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
HUM broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.